Ascendiant Capital Maintains Buy on ENDRA Life Sciences, Lowers Price Target to $30
Benzinga Newsdesk 10 months ago
NewsPrice TargetAnalyst Ratings
Ascendiant Capital analyst Edward Woo maintains ENDRA Life Sciences (NASDAQ:NDRA) with a Buy and lowers the price target from $38 to $30.
Ascendiant Capital analyst Edward Woo maintains ENDRA Life Sciences (NASDAQ:NDRA) with a Buy and lowers the price target from $38 to $30.